News Releases

Investor Alerts

Apr 16, 2021

Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
Mar 25, 2021

Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
Mar 15, 2021

Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported...
Feb 17, 2021

Avidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
Jan 21, 2021

Avidity Biosciences Appoints W. Michael Flanagan, Ph.D. as Chief Technical Officer

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...

Show per page